Navigation Links
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/30/2009

lation of PI-3 kinase is implicated in a large proportion of human cancers including breast, glioma, colon, ovarian, prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous administration. The compound has been shown to have anti-tumor activity both as a single agent and in combination with other agents in a number of human tumor models. Oncothyreon initiated a Phase 1 trial of PX-866 in patients with advanced metastatic cancer in June 2008.

About PX-12

PX-12 is a small molecule irreversible inhibitor of the redox protein thioredoxin. Thioredoxin is involved in the first unique step in DNA synthesis. Thioredoxin also provides control over a number of transcription factors affecting cell proliferation and death through the mechanism of redox regulation.

An initial Phase 1 trial involving 38 patients with advanced metastatic cancer showed that PX-12 was well tolerated and produced a decrease in plasma concentrations of thioredoxin that was significantly correlated with increased patient survival. Fifteen of the 38 patients achieved stable disease of up to 322 days. A randomized Phase 2 trial comparing two dose levels of PX-12 in up to 80 patients at three sites with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen was initiated in January 2007. Enrollment in this trial was terminated in early 2009. The Company intends to seek a partner for further development of this drug candidate.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to impr
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
(Date:5/4/2015)... May 04, 2015 Marianjoy ... patients with arm and hand impairments by acquiring ... its Oakbrook Terrace network site. , Secured through ... is a highly-regarded treatment option for patients with ... Armeo®Spring, Marianjoy becomes one of just four Illinois ...
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
(Date:5/1/2015)... A new report by  visiongain  forecasts the ... in 2019. That revenue forecast and others appear in  ... ,  published in March 2015. ... and qualitative analyses of the antithrombotic drugs market. Visiongain ... London, UK . It produces analyses to ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... SCOTTSDALE, Ariz., Aug. 22 Regenesis Biomedical, ... Wound Therapy,System, announced today the addition of two ... directors are Peter G. Savas, Chairman and CEO ... principal with,Bederson and Company., (Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008 ...
... VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: ... as,custirsen sodium, received Fast Track designation from the ... docetaxel for progressive,metastatic prostate cancer. OGX-011 is currently ... and breast cancer, and is designed to,inhibit the ...
... TSX Exchange Symbol: RVX, CALGARY, Aug. 21 ... announce that it will host a live,teleconference on ... provide a corporate,update of the Company. Following the ... session., The webcast can be accessed at ...
Cached Biology Technology:Regenesis Biomedical Announces Additions to Board of Directors 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Resverlogix Notice of Conference Call & Webcast 2
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... cancer cells facing potentially lethal antiestrogen therapy recycle to ... cancer cells have receptors for the hormone estrogen, which ... Patients typically get an antiestrogen such as tamoxifen for ... says Dr. Patricia V. Schoenlein, cancer researcher in the ...
... Madison, WI 1 OCTOBER 2008 Not only ... Houston,s George R. Brown Convention Center, beginning this weekend, ... seven scientific societies, but they are bringing focus to ... Meeting under the theme of "Celebrating the International Year ...
... (NorthShore) and Northwestern University have discovered that fiber optic ... blood levels in the colonic lining (mucosa) in humans, ... cancer. The study appears in the October ... of the American Gastroenterological Association (AGA) Institute. ...
Cached Biology News:Breast cancer cells recycle to escape death by hormonal therapy 2Breast cancer cells recycle to escape death by hormonal therapy 3Earth scientists keep an eye on Texas 2Earth scientists keep an eye on Texas 3Earth scientists keep an eye on Texas 4Earth scientists keep an eye on Texas 5Breakthrough optical technology to assess colon cancer risk, accuracy 2Breakthrough optical technology to assess colon cancer risk, accuracy 3
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Biology Products: